entertainment -WSS

entertainment

author：fashion 2025-09-27 09:40:26 - browse：1

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： CDC advisers recommend seasonal use of Pfizer RSV shot

WSS

It's been 20 years since Dolly the sheep. Where's my clone?

Grail is spending more than ever lobbying Congress

Thermo Fisher plant for manufacturing gene therapies to expand

Doctor appointment wait times are getting worse

Australia's humpback populations rebound raising hopes of marine scientists

Emergency workers more likely to restrain Black patients: study

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

It's been 20 years since Dolly the sheep. Where's my clone?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

STAT Virtual Event: Putting AI to the Test

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout LOUD podcast: possible new ALS drug, artificial wombs

Hollywood unions extend contract negotiations for actors

Ukraine and a new approach to mental health in war

focus

Ukraine and a new approach to mental health in war

Experts study whether long Covid risk adds up with each reinfection

Connecting traumatic brain injury and domestic violence

Intarcia’s device

Biotech lab space demand falls sharply

Make 'food is medicine' a key part of White House nutrition meeting

focus

hotspot

entertainment

hotspot